Advertisement

Neurotherapeutics

, Volume 15, Issue 2, pp 452–458 | Cite as

Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia

  • Laura M. Scorr
  • Michael R. Silver
  • John Hanfelt
  • Elaine Sperin
  • Alan Freeman
  • H. A. Jinnah
  • Stewart A. Factor
Original Article

Abstract

Oromandibular dystonia (OMD) causes involuntary movements of masticatory and lingual muscles impairing eating, speaking, and swallowing. Treatment options are limited. The objective of this study was to determine the safety and efficacy of abobotulinumtoxinA (aboBoNTA) in OMD. A dose-finding study (phase 1) followed by a single session, prospective, single-blind trial (phase 2) was carried out. OMD subjects were evaluated at baseline, 6 and 12 weeks. Muscles injected were tailored to individual symptoms using EMG guidance, but the aboBoNTA dose for each muscle was pre-specified based on phase 1 results. Evaluations were Global Dystonia Rating Scale (GDS), Unified Dystonia Rating Scale (UDRS), Clinical Global Impression (CGI) improvement and severity, and quality of life (OMDQ-25). Adverse events were monitored. The lowest dosage in phase 1 resulted in adverse effects in two of three patients and thus was used in phase 2. In phase 2, adverse effects were observed in 50% of subjects including dysphagia, voice change, and soft palate weakness. Most were mild. Significant improvement was seen in quality of life (OMDQ-25), speech (BFMq21), and change in GDS, UDRS, CGI severity assessed by the unblinded investigator, but not in blinded video ratings. We conclude that aboBoNTA therapy in this study was associated with improved quality of life and was generally well tolerated in OMD, but occurrence of dysphagia dictated the importance of using low genioglossus dosing. Face to face assessment appears to be more sensitive than video assessment for change in OMD severity. Consideration of the disability in OMD places constraints on traditional placebo-control trial design. Development of novel trial designs is warranted.

Keywords

Dystonia Oromandibular dystonia AbobotulinumtoxinA Quality of life Clinical trial 

Notes

Author Roles

Scorr: drafting and revising manuscript, analysis or interpretation of data, acquisition of data

Silver: drafting and revising manuscript, study concept or design, obtaining funding

Hanfelt: drafting and revising manuscript, analysis or interpretation of data

Sperin: drafting and revising manuscript, acquisition of data

Freeman: drafting and revising manuscript, acquisition of data

Jinnah: drafting and revising manuscript, analysis or interpretation of data, acquisition of data

Factor: drafting and revising manuscript, study concept or design, analysis or interpretation of data, acquisition of data, study supervision or coordination, obtaining funding

Author Disclosures

Scorr: none

Silver: none

Hanfelt: none

Sperin: none

Freeman: Honorarium Lundbeck

Jinnah: Dr. Jinnah is director of the Dystonia Coalition, which receives the majority of its support through National Institutes of Health (NIH) grants NS065701 and TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and the National Institute of Neurological Disorders and Stroke. The Dystonia Coalition has received additional material or administrative support from industry sponsors (Allergan Inc. and Merz Pharmaceuticals) as well as private foundations (Beat Dystonia, The Benign Essential Blepharospasm Foundation, Cure Dystonia Now, Dystonia Inc., Dystonia Ireland, The Dystonia Medical Research Foundation, The European Dystonia Federation, The Foundation for Dystonia Research, The National Spasmodic Dysphonia Association, The National Spasmodic Torticollis Association, Tyler’s Hope for a Dystonia Cure). Dr. Jinnah has also received research or training grants from the NIH, Pharmaceutical Companies (Ipsen Inc. and Merz Pharmaceuticals) and Private Foundations (the Benign Essential Blepharospasm Research Foundation, Cure Dystonia Now, Dystonia Medical Research Foundation, and the Lesch-Nyhan Syndrome Children’s Research Foundation). He also has served on an advisory board or as a consultant for Allergan, Inc., Ipsen Pharmaceuticals, Psyadon Therapeutics, Retrophin Inc., and Saol Therapeutics.

Factor: Honoraria: Neurocrine, Lundbeck, Auspex/Teva, Avanir, Cynapsus, Adamas, UCB.

Grants: Ipsen, Medtronics, Teva, US World Meds, Cynapsus Therapeutics, Solstice, Vaccinex, Voyager, CHDI Foundation, Michael J. Fox Foundation, NIH

Royalties: Demos, Blackwell Futura for textbooks, Uptodate

Funding

Ipsen Pharmaceuticals supported this study.

SAF is supported by the Sartain Lanier Family Foundation.

Supplementary material

13311_2018_620_MOESM1_ESM.pdf (1.2 mb)
ESM 1 (PDF 1225 kb)
13311_2018_620_MOESM2_ESM.docx (25 kb)
ESM 2 (DOCX 24 kb)

References

  1. 1.
    Termsarasab P, Tanenbaum DR, Frucht SJ. The phenomenology and natural history of idiopathic lower cranial dystonia. J Clin Mov Disord 2014;1:3.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Evatt ML, Freeman A, Factor S. Adult-onset dystonia. Handbook of clinical neurology 2011;100:481–511.CrossRefPubMedGoogle Scholar
  3. 3.
    Singer C, Papapetropoulos S. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia. Parkinsonism Relat Disord 2006;12:115–118.CrossRefPubMedGoogle Scholar
  4. 4.
    Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord 2010;16:438–441.CrossRefPubMedGoogle Scholar
  5. 5.
    Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ, 3rd. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3:188–194.CrossRefPubMedGoogle Scholar
  6. 6.
    Le KD, Nilsen B, Dietrichs E. Prevalence of primary focal and segmental dystonia in Oslo. Neurology 2003;61:1294–1296.CrossRefPubMedGoogle Scholar
  7. 7.
    Tolosa E, Kulisevsky J, Fahn S. Meige syndrome: primary and secondary forms. Adv Neurol 1988;50:509–515.PubMedGoogle Scholar
  8. 8.
    Williams L, McGovern E, Kimmich O, et al. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur J Neurol 2017;24:73–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53:2102–2107.CrossRefPubMedGoogle Scholar
  10. 10.
    Papapetropoulos S, Singer C. Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. Head Face Med 2006;2:47.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rosales RL, Ng AR, Santos MM, Fernandez HH. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport(R)) injections for oromandibular, lingual, and truncal-axial dystonias. Int J Neurosci 2011;121 Suppl 1:44–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Merz RI, Deakin J, Hawthorne MR. Oromandibular dystonia questionnaire (OMDQ-25): a valid and reliable instrument for measuring health-related quality of life. Clin Otolaryngol 2010;35:390–396.CrossRefPubMedGoogle Scholar
  13. 13.
    Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Archives of Otolaryngology-Head & Neck Surgery 2001;127:389–392.CrossRefGoogle Scholar
  14. 14.
    Charous SJ, Comella CL, Fan W. Jaw-opening dystonia: Quality of life after botulinum toxin injections. Ear Nose Throat J 2011;90:E9.PubMedGoogle Scholar
  15. 15.
    Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 2006;13 Suppl 1:21–29.CrossRefPubMedGoogle Scholar
  16. 16.
    Karp BI, Alter K. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm. Semin Neurol 2016;36:84–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Teemul TA, Patel R, Kanatas A, Carter LM. Management of oromandibular dystonia with botulinum A toxin: a series of cases. Br J Oral Maxillofac Surg 2016;54:1080–1084.CrossRefPubMedGoogle Scholar
  18. 18.
    Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013;67:94–114.CrossRefPubMedGoogle Scholar
  19. 19.
    Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope 2013;123:3078–3083.CrossRefPubMedGoogle Scholar
  20. 20.
    Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000;68:186–190.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;28:863–873.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Galpern WR, Coffey CS, Albanese A, et al. Designing clinical trials for dystonia. Neurotherapeutics 2014;11:117–127.CrossRefPubMedGoogle Scholar
  23. 23.
    Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord 2007;22:1917–1921.CrossRefPubMedGoogle Scholar
  24. 24.
    Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, Dystonia Study G. Rating scales for dystonia: a multicenter assessment. Mov Disord 2003;18:303–312.CrossRefPubMedGoogle Scholar
  25. 25.
    Perez Lloret S, Piran Arce G, Rossi M, Caivano Nemet ML, Salsamendi P, Merello M. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. Mov Disord 2007;22:107–111.CrossRefPubMedGoogle Scholar
  26. 26.
    Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73–77.CrossRefPubMedGoogle Scholar
  27. 27.
    Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616–623.CrossRefPubMedGoogle Scholar
  28. 28.
    Lee SJ, McCall WD, Jr., Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil 2010;89:16–23.CrossRefPubMedGoogle Scholar
  29. 29.
    Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989;98:93–97.CrossRefPubMedGoogle Scholar
  30. 30.
    Charles PD, Davis TL, Shannon KM, Hook MA, Warner JS. Tongue protrusion dystonia: treatment with botulinum toxin. South Med J 1997;90:522–525.CrossRefPubMedGoogle Scholar
  31. 31.
    Gonzalez-Alegre P, Schneider RL, Hoffman H. Clinical, Etiological, and Therapeutic Features of Jaw-opening and Jaw-closing Oromandibular Dystonias: A Decade of Experience at a Single Treatment Center. Tremor and other hyperkinetic movements 2014;4:231.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Defazio G, Lepore V, Abbruzzese G, et al. Reliability among neurologists in the severity assessment of blepharospasm and oromandibular dystonia: a multicenter study. Mov Disord 1994;9:616–621.CrossRefPubMedGoogle Scholar
  33. 33.
    Del Sorbo F, Albanese A. Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials. Toxicon 2015;107:89–97.CrossRefPubMedGoogle Scholar
  34. 34.
    Nastasi L, Mostile G, Nicoletti A, Zappia M, Reggio E, Catania S. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. Journal of neurology 2016;263:1702–1708.CrossRefPubMedGoogle Scholar
  35. 35.
    Truong DD, Hermanowicz NS. Clinical evaluation of bidirectional torticollis. Mov Disord 1990;5:181.CrossRefPubMedGoogle Scholar
  36. 36.
    Yun JY, Kim JW, Kim HT, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord 2015;30:206–213.CrossRefPubMedGoogle Scholar
  37. 37.
    Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013;28:1775–1783.CrossRefPubMedGoogle Scholar
  38. 38.
    Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y) 2012;2.Google Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2018

Authors and Affiliations

  • Laura M. Scorr
    • 1
  • Michael R. Silver
    • 1
  • John Hanfelt
    • 2
  • Elaine Sperin
    • 1
  • Alan Freeman
    • 1
  • H. A. Jinnah
    • 1
  • Stewart A. Factor
    • 1
  1. 1.Department of NeurologyEmory UniversityAtlantaUSA
  2. 2.Department of Biostatistics and Bioinformatics Emory UniversityAtlantaUSA

Personalised recommendations